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Introduction
Fifteen years ago, what was to become OMERACT met for
the first time in The Netherlands to discuss ways in which
the multitude of outcomes in assessments of the effects of
treatments for rheumatoid arthritis might be standard-
ised. In Trials, Tugwell et al have described the need for,
and success of, this initiative [1] and Cooney and col-
leagues have set out their plans for a corresponding initi-
ative for ulcerative colitis [2]. Why do we need such
initiatives? What's the problem? And are these and other
initiatives the solution?
What's the problem?
Every year, millions of journal articles are added to the
tens of millions that already exist in the health literature,
and tens of millions of web pages are added to the hun-
dreds of millions currently available. Within these, there
are many tens of thousands of research studies which
might provide the evidence needed to make well-
informed decisions about health care. The task of working
through all this material is overwhelming enough, with-
out then finding that the studies of relevance to the deci-
sion you wish to make all describe their findings in
different ways, making it difficult if not impossible to
draw out the relevant information. Of course, you might
be able to find a systematic review, but even then there is
no guarantee that the authors of that review will not have
been faced with an insurmountable task of bringing
together and making sense of a variety of studies that used
a variety of outcomes and outcome measures.
These difficulties are great enough but the problem gets
even worse when one considers the potential for bias. If
researchers have measured a particular outcome in a vari-
ety of ways, (for example using different pain instruments
filled in by different people at different times) they might
not report all of their findings from all of these measures.
Studies have highlighted this problem in clinical trials,
showing that this selectivity in reporting is usually driven
by a desire to present the most positive or statistically sig-
nificant results [3]. This will mean that, where the original
researcher had a choice, the reader of the clinical trial
report might be presented with an overly optimistic esti-
mate of the effect of an intervention and therefore be led
towards the wrong decision.
In the 1990s, the potential scale of the problem of multi-
ple outcome measures was highlighted in mental health
by a comprehensive descriptive account of randomised
trials in the treatment of people with schizophrenia.
Thornley and
Adams identified a total of 2000 such trials, which had
assessed more than 600 different interventions. However,
these trials had included an even greater number of rating
scales for mental health than the number of interventions:
640 [4]. The potential for biased reported and the chal-
lenges of comparing the findings of different trials of dif-
ferent interventions using different ways of measuring
illness make the identification of effective, ineffective and
unproven treatments for this condition especially difficult
[5]. This is true whether the readers of the report of a clin-
ical trial are trying to use it to inform their decisions, or
whether they are trying to combine similar trials within a
systematic review. Thornley and Adams, who had done
the descriptive study of the large number of rating scales
in mental health trials, were faced with this very problem
in a review of chlorpromazine. They concluded that
review with the following implications for research, "if
rating scales are to be employed, a concerted effort should
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be made to agree on which measures are the most useful.
Studies within this review reported on so many scales that,
even if results had not been poorly reported, they would
have been difficult to synthesise in a clinically meaningful
way." [6].
What's the solution?
If we want to choose the shortest of three routes between
two towns, how would we cope if told that one is 10 kilo-
metres and another is 8 miles? Doing that conversion
between miles and kilometres might not be too much of
a problem, but what if the third route was said to be 32
furlongs? Now, imagine that the measurements had all
been taken in different ways. One came from walking the
route with a measuring wheel, one from an estimate based
on the time taken to ride a horse between the two towns
and one from using a ruler on a map. To make a well
informed choice we would want the distances to be avail-
able to us in the same units, measured in the same ways.
Making decisions about health care should be no differ-
ent. We want to compare and contrast research findings
on the basis of the same outcomes, measured in the same
ways.
Achieving this is not straightforward, but it is not impos-
sible. Key steps are to decide on the core outcome meas-
ures and, in some cases, the core baseline variables, and
for these to then be included in the conduct and reporting
of research studies. One of the earliest examples is an ini-
tiative by the World Health Organisation in the late
1970s, relating to cancer trials. Meetings on the Standard-
ization of Reporting Results of Cancer Treatment took
place in Turin (1977) and in Brussels two years later. More
than 30 representatives from cooperative groups doing
randomised trials in cancer came together and their dis-
cussions led to a WHO Handbook of guidelines on the
minimal requirements for data collection in cancer trials
[7,8].
OMERACT has also grown by trying to reach a consensus
among major stakeholders in the field of rheumatology
[1] and the IMMPACT recommendations for chronic pain
trials have arisen in a similar way [9]. Other approaches
have included the use of literature surveys to identify the
variety of outcome measures that have been used and
reported, followed by group discussion. This is the case
with low back pain [10], colon cancer [11] and an e-Delhi
survey in maternity care [12].
Having developed these lists of outcomes measures,
researchers need to use them and systematic reviewers
need to build their reviews around them. These sets of
standardised outcomes measures are not meant to stifle
the development and use of other outcomes. Rather, they
provide a core set of outcome measures, which researchers
should use routinely. Researchers wishing to add other
outcome measures in the context of their own trial would
continue to do so but, when reporting their trial, selective
reporting should be avoided through the presentation of
the findings for both the core set and all additional out-
come measures they collected. Furthermore, the use of the
outcome measures in these core sets should not be
restricted to research studies. They are also relevant within
routine practice. If they are collected within such practice,
they would help the provider and the receiver of health
care to assess their progress and facilitate their under-
standing of the relevance to them of the findings of
research.
Journals such as Trials can help by highlighting initiatives
such as those discussed in rheumatology [1] and ulcera-
tive colitis [2]. They should encourage researchers to
report their findings for the outcome measures in the core
sets, and provide them with the space to do so. This will
allow readers and systematic reviewers to make best use of
the reported trials.
Conclusion
When there are differences among the results of similar
clinical trials, the fundamental issues of interest to people
making decisions about health care are likely to concern
the interventions that were tested, the types of patient in
the study, or both; not the different outcome measure
used. The latter is important but if one remembers that the
studies were probably not done to assess differences
between the various ways of measuring outcomes, but,
rather, differences between the interventions, the benefits
of consistency become obvious. Achieving consistency is
not something that can be left to serendipity. It will
require consensus, guidelines and adherence. The papers
in Trials and others mentioned in this commentary show
how this might happen.
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